Although EGFR (Maemondo et al, 2010) and ALK (Solomon et al, 2014) inhibitors are established in EGFR mutant and ALK rearranged lung cancer, there are currently no molecularly targeted agents licensed for use in the remainder of adenocarcinomas (NSCLC-adeno-EGFRWT/ALKnon-rearranged). The gene discussed is ALK; the disease is adenocarcinoma.